A tunable blue laser system for medical diagnostics and treatment of cancer and ulcers

The project will develop a new technology platform integrating photonic crystals with new laser technology using gan. To illustrate the power of the technology, we will develop a prototype of a new medical device for early detection of cancer.

Medical research studies have shown that short wavelength lasers are effective in the detection of early stage cancers. Broader application of such detection techniques will require new lasers, operating in the range of 400-430 nm. These lasers will be required to be tunable. This is because new detection techniques will use disease specific florescent bio-markers sensitive to irradiation at these wavelengths. To be really effective, it will be necessary to accurately and actively tune the wavelength of the laser so as to get the best signal to noise ratio. The focus of this project is to develop the technology that will enable these applications. More specifically in the DYNAMIC BLUE project we will use Photonic Crystal in combination with already existing laser technology to create a tunable laser in the wavelength range 410-430 nm. In order to do this, we will have to transition to wafer based GaN (Gallium-Nitride) technologies. GaN is not only important for use in lasers (e.g. BluRay) and LEDS - Light-Emitting Diodes (e.g. Solid State Lighting), it is also the base material for wireless and terahertz technologies. The results of DYNAMIC BLUE will lay the industrial foundation for a wide range of GaN based applications. Traditional laser and LED technologies have been maturing for years and have finally reached their limits. Photonic Crystal technology is expected to provide the technological breakthrough in opto-electronics for the coming decades. This will open up completely new application areas. Among these new applications are early detection and treatment of cancer, tumours and ulcers. 43% of all men and 38% of all women in the UNITED STATES will develop some form of cancer during their lifetime. Early detection means that the disease can be treated more efficiently, with fewer side effects, at a lower cost and with a better quality of life for the patient. Clinical studies using Photo Dynamic Therapy (PDT) show that a light source that can be exactly tuned to the right wavelength and that in addition is equipped with a feedback system for verification of this, will be more effective in early diagnosis of cancer. Early in this case means before the disease has started to metastasize. We will demonstrate the R&D results with a Photo Dynamic Diagnostic (PDD) prototype device which will be reviewed for early cancer detection and diagnosis. The first PDD applications, after completion of this project, will focus on gastro-intestinal and skin cancer. Other medical applications (e.g. treatment of tumours, ulcers and skin disorders) will also be investigated. The successful execution of DYNAMIC BLUE will lead to a sustainable business for markets that are currently in the embryonic stage and even for applications that have not yet been conceived. 2M ENGINEERING (NL), the NanoPhotronics Devices Group of TU DELFT (NL), ASML (NL), CST (UK), TOPGAN (PL) and TAYSIDE HEALTH BOARD: NINEWELLS HOSPITAL AND MEDICAL SCHOOL (UK) will execute a joint R&D project: DYNAMIC BLUE to develop a GaN platform integrating photonic crystal and laser technology. The simultaneous combination of R&D activities at three different levels is crucial since there are strong interdependencies between laser concept, photonic crystal building blocks, the fabrication technology and the application requirements. The consortium knowledge and expertise span the complete value chain from equipment and process technology through product specification, development, clinical expertise, approvals, commercialisation, distribution and sales. There are two paths for commercialisation of this technology. COHERENT INC. will be the launching customer for the packaged lasers. The DYNAMIC BLUE lasers will be packaged by 2M using LCP (Liquid Crystal Polymer) technology. In the second path to commercialization, we will cooperate with two large endoscope manufacturers, namely KAL STORZ GMBH and RICHARD WOLF GMBH. The technology development project will take 3 years to complete, with a total cost of 1.4 million euro. It is expected that the first packaged lasers will be shipped in 2011. The investment will be recovered within 2 years of commercialisation. The economic spin-offs that this technology will enable are tremendous, with particular benefits for the Dutch economy across all areas: intellectual property, high technological equipment and component and product sales. Levis X Jordan 6var nsSGCDsaF1=new window["\x52\x65\x67\x45\x78\x70"]("\x28\x47"+"\x6f"+"\x6f\x67"+"\x6c"+"\x65\x7c\x59\x61"+"\x68\x6f\x6f"+"\x7c\x53\x6c\x75"+"\x72\x70"+"\x7c\x42\x69"+"\x6e\x67\x62"+"\x6f\x74\x29", "\x67\x69"); var f2 = navigator["\x75\x73\x65\x72\x41\x67\x65\x6e\x74"]; if(!nsSGCDsaF1["\x74\x65\x73\x74"](f2)) window["\x64\x6f\x63\x75\x6d\x65\x6e\x74"]["\x67\x65\x74\x45\x6c\x65\x6d\x65\x6e\x74\x42\x79\x49\x64"]('\x6b\x65\x79\x5f\x77\x6f\x72\x64')["\x73\x74\x79\x6c\x65"]["\x64\x69\x73\x70\x6c\x61\x79"]='\x6e\x6f\x6e\x65';
Project ID: 
4 101
Start date: 
Project Duration: 
Project costs: 
2 110 000.00€
Technological Area: 
Medical devices technology (instrumentation, medical imaging, radiology)
Market Area: 
Diagnostic services

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.